Jack Henry & Associates (JKHY) continues to speak volumes in the bio-tech market despite sporadic underperformances compared to competitors. While some daily losses were reported, the company also enjoyed days when their stocks outperformed the competition. Notable financial institutes including Savant Capital LLC, International Assets Investment, Russell Investments Group Ltd., and Raymond James & associates, have shown interest in JKHY by acquiring shares, with Russell Investments Group further adjusting their JKHY stock position. Furthermore, the stock’s earnings per share (EPS) has repeatedly surpassed analyst estimates, contributing to strong Q3 earnings that topped revenue estimates year-over-year. Despite this, JKHY stocks underwent a slight decrease following their last earnings report. Plans for future earnings are expected to continue the trend of topping estimates as Q3 2024 earnings are projected at $1.26 per share. JKHY has been actively expanding their client base, recently securing a deal with United Bank. The company is enduring a healthy financial year, demonstrated through their announced increase in quarterly dividends and establishment of an endowed scholarship fund. However, JKHY also mourns the loss of board member Laura Kelly. JKHY is set to elevate Greg Adelson to CEO in July 2024 with Shanon McLachlan to follow as COO. The company's commitment to progress is reflected in its continual product development and distribution.
Henry Jack Associates JKHY News Analytics from Mon, 03 Jul 2023 07:00:00 GMT to Wed, 08 May 2024 21:20:00 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 1
